EP0371564B1 - (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives - Google Patents

(1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives Download PDF

Info

Publication number
EP0371564B1
EP0371564B1 EP89203014A EP89203014A EP0371564B1 EP 0371564 B1 EP0371564 B1 EP 0371564B1 EP 89203014 A EP89203014 A EP 89203014A EP 89203014 A EP89203014 A EP 89203014A EP 0371564 B1 EP0371564 B1 EP 0371564B1
Authority
EP
European Patent Office
Prior art keywords
formula
hydrogen
alkyl
parts
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP89203014A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0371564A3 (en
EP0371564A2 (en
Inventor
Eddy Jean Edgard Freyne
Marc Gaston Venet
Alfons Herman Margaretha Raeymaekers
Gerard Charles Sanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888827821A external-priority patent/GB8827821D0/en
Priority claimed from GB888827822A external-priority patent/GB8827822D0/en
Priority claimed from GB888827820A external-priority patent/GB8827820D0/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP0371564A2 publication Critical patent/EP0371564A2/en
Publication of EP0371564A3 publication Critical patent/EP0371564A3/en
Application granted granted Critical
Publication of EP0371564B1 publication Critical patent/EP0371564B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Definitions

  • the present invention is concerned with novel compounds of formula the pharmaceutical acceptable acid addition salts thereof and the stereochemically isomeric forms thereof, wherein
  • Ar 1 is phenyl, substituted phenyl, naphthalenyl, pyridinyl, imidazolyl, triazolyl, thienyl, furanyl or thiazolyl and Ar 2 is phenyl or substituted phenyl; said substituted phenyl in Ar 1 or Ar 2 being phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl, C 1 - 6 alkyl, C 1-6 alkyloxy, cyano, amino, mono- and di(C 1-6 alkyl)amino, nitro, carboxyl, formyl and C 1-6 alkyloxycarbonyl.
  • halo is generic to fluoro, chloro, bromo and iodo
  • C 1-6 alkyl is meant to include straight chained and branched saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl, pentyl, hexyl
  • C 1-10 oalkyl is meant to include the higher homologs of "C 1 - 6 alkyl” containing 1-10 carbon atoms
  • C 3 - 7 cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl
  • C 2 - 6 alkenyl defines straight chained and branched hydrocarbon radicals containing one double bond having from 2 to
  • the moiety hereinafter referred as the 1H-azol-1-ylmethyl moiety may be substituted on either the 5, 6, 7 or 8 position of the bicyclic ring system, the 6 or 7 position being preferred, the 6 position being most perferred.
  • the acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form.
  • the latter can conveniently be obtained by treating the base form with appropriate acids such as, for example, inorganic acids, such as hydrohalic acid, e.g.
  • organic acids such as, for example, acetic, hydroxyacetic, propanoic, 2-hydroxypropanoic, 2- oxo
  • acid addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates.
  • said compound will be synthesized by stereoselective methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
  • the compounds of formula (I) may also contain in their structure a tautomeric system and consequently these compounds can be present in each of their tautomeric forms.
  • Particular compounds of the present invention are those compounds of formula (I) wherein R is hydrogen or C 1-4 alkyl; and/or Y is hydrogen, C i - 6 alkyl, C 3 - 7 cycloalkyl, phenyl, substituted phenyl, pyridinyl, imidazolyl or thienyl; and/or Z is a radical of formula (a-1), (a-2), (a-3) or (a-4) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 10 , R 11 and R 12 each independently are hydrogen or C1-4alkyl, and R 7 and R 9 each independently are hydrogen, C 1-4 alkyl, C 1-4 alkyloxy or halo; and/or Z is a radical of formula (b-1), (b-2), (b-3), (b-4), (b-5), or (b-6) wherein R 13 is hydrogen, C 1-4 alkyl, trifluoromethyl or phenyl
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (a-1) are selected from 6-[(4-fluorophenyl)(1_H-imidazol-1-yl)methyl]-2(1_H)-quinolinone, the pharmaceutically acid addition salts and possible stereoisomeric forms thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (a-2) are selected from 6-[(3-chlorophenyl)(1_H-imidazol-1-yl)methyl]-3,4-dihydro-2(1_H)-quinolinone and 3,4-dihydro-6-[(1H-imidazol-1-yl)-phenylmethyl]-2(1H)-quinolinone, the pharmaceutically acceptable acid addition salts and possible stereoisomers thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (a-3) are selected from 6-[-(1_H-1,2,4-triazol-1-yl)[3-(trifluoromethyl)phenyl]methyl]quinoline, the pharmaceutically acceptable acid addition salts and possible stereoisomers thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (b-2) are selected from 3,4-dihydro-6-[(1H-imidazol-1-yl)phenylmethyl]-2(1_H)-quinazolinone, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (b-5) are selected from 6-[-(1H-imidazol-1-yl)phenylmethyl]-3-methyl-2,4(1_H,3_H)-quinazolinedione, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (b-5) are selected from 6-[-(1H-imidazol-1-yl)phenylmethyl]-4(3_H))-quinazolinone, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (c-1) are selected from 6-[-(1H-imidazol-1-yl)phenylmethyl]quinoxaline and 6-[(4-fluoro phenyl)(1H-imidazol-1-yl)methyl]quinoxaline, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof.
  • R is hydrogen;
  • Y is hydrogen, C 1-4 alkyl, cyclopropyl, cyclopentyl or cyclohexyl;
  • R 26 is hydrogen;
  • R 27 is hydrogen, C 1-4 alkyl, naphthalenyl, thienyl, pyridinyl, imidazolyl, phenyl or phenyl substituted with 1 or 2 substituents each independently selected from methyl, halo, hydroxy and methoxy; and
  • n is 0.
  • Most preferred compounds of formula (I) wherein Z is a radical of formula (c-2) are selected from 6-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-phenyl-2(1_H)-quinoxa linone, 6-[1-(1H-imidazol-1-yl)-2-methylpropyl]-3-propyl-2(1H)-quinoxalinone, 3-(3-fluorophenyl)-6-[1-(1_H-imidazol-1-yl)-2-methylpropyl]-2(1_H)-quinoxalinone, the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof.
  • the compounds of formula (I) can he prepared by N-alkylating an azole of formula (II) or an alkali metal salt thereof with a quinoline, quinolinone, quinazoline or quinoxaline derivative of formula (III).
  • W represents an appropriate reactive leaving group such as, for example, halo, e.g., fluoro, chloro, bromo, iodo or a sulfonyloxy group, e.g. 4-methylbenzenesulfonyloxy, benzenesulfonyloxy, 2-naphthalenesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy reactive leaving groups.
  • halo e.g., fluoro, chloro, bromo, iodo
  • a sulfonyloxy group e.g. 4-methylbenzenesulfonyloxy, benzenesulfonyloxy, 2-naphthalenesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy reactive leaving groups.
  • N-alkylation is conveniently carried out by stirring the reactants in the presence of a suitable solvent such as, for example, an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; an ester, e.g. ethyl acetate, y-butyrolacetone; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone; an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran; a polar aprotic solvent, e.g.
  • a suitable solvent such as, for example, an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; an ester, e.g. ethyl acetate, y-butyrolacetone; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone; an ether
  • Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction and in some cases the reaction may even be carried out at the reflux temperature of the reaction mixture.
  • an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, amide or hydride, e.g. sodium hydroxide, potassium hydroxide, potassium carbonate, sodium hydride or an organic base, such as, for example, N,N-dimethyl-4-pyridinamine, pyridine, N,N-diethylethanamine or N-(1-methylethyl)-2-propanamine may be employed to pick up the acid which is liberated during the course of the reaction.
  • an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, amide or hydride, e.g. sodium hydroxide, potassium hydroxide, potassium carbonate, sodium hydride or an organic base, such as, for example, N,N-dimethyl-4-pyridinamine, pyridine, N,N-diethylethanamine or N-(1-methylethyl)-2-propan
  • azole (II) it may be advantageous to use an excess of the azole (II) or to convert the azole first into a suitable salt form thereof such as, for example, an alkali or earth alkaline metal salt, by reacting (II) with an appropriate base as defined hereinabove and subsequently using said salt form in the reaction with the alkylating reagent of formula (III).
  • a suitable salt form thereof such as, for example, an alkali or earth alkaline metal salt
  • an appropriate base as defined hereinabove
  • said salt form in the reaction with the alkylating reagent of formula (III).
  • N-alkylation reaction under an inert atmosphere such as, for example, oxygen-free argon or nitrogen gas.
  • Said alkylation may also be carried out by applying art-known conditions of phase transfer catalysis reactions.
  • P 1 represents a protective group such as, for example, C 1 - 6 alkylcarbonyl, C 1 - 6 alkyloxycarbonyl, arylcarbonyl or a tri(C l - 6 alkyl)silyl group.
  • reaction of (II-x) with (III) first yields a 1- protected imidazolium salt of formula (IV) which may in situ, or if desired, after isolating and further purifying it, be deprotected by stirring it in an aqueous basic or acidic solution.
  • W- is an anion arising from an acid such as, for example, hydrochloric acid, hydrobromic acid, methanesulfonic acid, 4-methylbenzenesulfonic acid acids.
  • the endo-N-alkylation reaction of (II-y) with (III) is carried out according to similar procedures as described hereinabove for the preparation of a compound of formula (I) starting from (III) and (II).
  • Said deamination reaction is conveniently conducted by reaction with an acidic nitrite solution in the presence of an appropriate reductant, or by reaction with an alkylnitrite such as, for example, 1,1-dimethylethylnitrite or isoamylnitrite.
  • said deamination reaction is conducted with an aqueous solution of nitrous acid or of a nitrite salt in a suitable acid in the presence of a reducing agent such as, for example, hypophosphorous acid, formic acid, at a lower temperature.
  • the compounds of formula (I) may also be prepared by reacting an intermediate of formula (V) with a reagent of formula (VI) such as, for example, a 1,1'-carbonylbis[1 H-imidazole].
  • a reagent of formula (VI) such as, for example, a 1,1'-carbonylbis[1 H-imidazole].
  • X represents C or S.
  • Said reaction may conveniently be conducted in a suitable solvent such as, for example, an ether, e.g. 1,4-dioxane, tetrahydrofuran; a halogenated hydrocarbon, e.g. di- or trichloromethane; a hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; N,N-dimethylformamide, N,N-dimethylacetamide, or a mixture of such solvents.
  • a suitable solvent such as, for example, an ether, e.g. 1,4-dioxane, tetrahydrofuran; a halogenated hydrocarbon, e.g. di- or trichloromethane; a hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; N,N-dimethylformamide, N,N-dimethylacetamide, or a mixture of such solvents.
  • the compounds of formula (I) may also be prepared by reacting a ketone or aldehyde of formula (VII) with an azole (II) in the presence of formic acid or formamides as reducing agents.
  • Said reductive alkylation can conveniently be conducted by stirring and heating the reagents in formic acid or formamides optionally in the presence of an acid catalyst.
  • An appropriate acid catalyst for using in this reaction is for example a mineral acid such as, hydrochloric acid, sulfuric acid or a sulfonic acid such as, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid. It may be appropriate to remove the water which is formed during the reaction by azeotropical distillation, distillation, complexation methods.
  • reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, distillation, crystallization, trituration and chromatography.
  • Some compounds of formula (I-a) can alternatively be prepared under similar conditions as are described in the literature for the preparation of quinolines or quinolinones by cyclizing an intermediate of formula or an appropriate derivative thereof.
  • the compounds of formula (1-a-1) can be prepared by cyclizing an intermediate of formula (IX).
  • the acid-catalysed cyclization of (IX) can generally be conducted by treating the intermediate amide (IX) with an appropriate acid such as, for example, sulfuric acid, a hydrohalic acid, e.g. hydrochloric acid, polyphosphoric acid strong acids, optionally at an enhanced temperature as described for example in J. Med. Chem. 1986, 29, 2427-2432.
  • the compounds of formula (1-a-1), may also be obtained by cyclizing an intermediate of formula (X).
  • the cyclization reaction of (X) may be conducted according to art-known cyclizing procedures as described in, for example, Synthesis 1975, 739.
  • the reaction is carried out in the presence of a suitable Lewis Acid, e.g. aluminum chloride either neat or in a suitable solvent such as, for example, an aromatic hydrocarbon, e.g. benzene, chlorobenzene, methylbenzene; halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane; an ether, e.g. tetrahydrofuran, 1,4-dioxane or mixtures of such solvents.
  • a suitable Lewis Acid e.g. aluminum chloride either neat or in a suitable solvent
  • an aromatic hydrocarbon e.g. benzene, chlorobenzene, methylbenzene
  • halogenated hydrocarbons e
  • Quinolinones of formula (l-a-1 ) may also be prepared by cyclizing an intermediate of formula (XI).
  • the cyclization of (XI) can generally be conducted by treating the intermediate propeneamide (XI) with an appropriate acid such as, for example, sulfuric acid, a hydrohalic acid, e.g. hydrochloric acid, polyphosphoric acid strong acids at room temperature or optionally at an enhanced temperature as described for example in J. Med. Chem. 1989, 32, 1552-1558 or J. Med. Chem. 1988, 31, 2048-2056.
  • an appropriate acid such as, for example, sulfuric acid, a hydrohalic acid, e.g. hydrochloric acid, polyphosphoric acid strong acids at room temperature or optionally at an enhanced temperature as described for example in J. Med. Chem. 1989, 32, 1552-1558 or J. Med. Chem. 1988, 31, 2048-2056.
  • the compounds of formula (I) wherein Z is a radical of formula (a-1) or (a-2) may be prepared by cyclizing an intermediate of formula (XII) or (XIII).
  • R 37 represents either a hydrogen or a C1 -4alkyl group.
  • the above mentioned cyclization reactions may be carried out by stirring and if desired heating the intermediate starting material, optionally in a suitable reaction-inert solvent.
  • Appropriate solvents for said cyclization reactions are for example, aromatic hydrocarbons, e.g. benzene, methylbenzene, dimethylbenzene; halogenated hydrocarbons, e.g.
  • ethers e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, alkanols, e.g. ethanol, propanol, butanol; ketones, e.g. 2-propanone, 4-methyl-2-pentanone; dipolar aprotic solvents, e.g. N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, methyl acetamide, pyridine, or mixtures of such solvents.
  • the water which is liberated during the cyclization reaction may be removed from the reaction mixture by azeotropical distillation.
  • Some compounds of formula (I-a-3), can be prepared by cyclizing an intermediate of formula (XIV). Said cyclization reaction may conveniently be conducted following similar cyclization procedures as described hereinabove for preparing (l-a-1 ) from (IX) by cyclizing an intermediate (XIV) in the presence of a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide, polyphosphate ester, sulfuric acid.
  • a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide, polyphosphate ester, sulfuric acid.
  • the compounds of formula (I-a-3) can be prepared by reacting an aniline of formula (VIII) with an ⁇ , ⁇ -unsaturated carbonyl synthon of formula (XV) in the presence of an oxidizing agent. Said reaction may be conducted by heating the reactants in the presence of an acid such as, for example, sulfuric acid, a hydrohalic acid, e.g. hydrochloric acid, polyphosphoric acid strong acids and a mild oxidizing agent.
  • an acid such as, for example, sulfuric acid, a hydrohalic acid, e.g. hydrochloric acid, polyphosphoric acid strong acids and a mild oxidizing agent.
  • oxidizing agents are for example arsenic acid, arsenic oxide, boric acid, ferric chloride, silver nitrate, nitrobenzene, 4-nitrobenzenesulfonic acid or a mixture of 4-nitrobenzoic acid and 4-aminobenzoic acid.
  • Compounds of formula (I-a-3) may also be prepared by condensing an ortho-acyl aniline of formula (XVI) with a ketone or aldehyde of formula (XVII). Said cyclization may convenienlty be conducted by mixing the reactants in a reaction-inert solvent such as, for example, water, an alcohol, e.g. methanol, butanol; an aromatic hydrocarbon, e.g.
  • a reaction-inert solvent such as, for example, water, an alcohol, e.g. methanol, butanol; an aromatic hydrocarbon, e.g.
  • benzene methylbenzene, dimethylbenzene, an ester, e.g., ethyl acetate; a halogenated hydrocarbon, e.g., trichloromethane, dichloromethane; or a mixture of such solvents, preferably in the presence of a mineral acid such as, for example, hydrochloric acid, sulfuric acid, a carboxylic acid such as, for example, formic acid, acetic acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid or in the presence of a dehydrating agent, such as polyphosphoric acid, phosphorous pentoxide.
  • a mineral acid such as, for example, hydrochloric acid, sulfuric acid, a carboxylic acid such as, for example, formic acid, acetic acid, or a sulfonic acid such as, for example, methanesul
  • Somewhat elevated temperatures may he appropriate to enhance the rate of the reaction and in some cases the reaction may he carried out at the reflux temperature of the reaction mixture. It may be appropriate to remove the water which is liberated during the course of the condensation reaction by azeotropical distillation.
  • the compounds of formula (I) wherein Z is a radical of formula (a-4) and R 10 is hydrogen, said compounds being represented by (I-a-4-a) can be prepared by cyclizing an intermediate of formula (XVIII).
  • the above mentioned cyclization reaction is preferably accomplished by stirring the intermediate (XVIII) in the presence of a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide, polyphosphate ester, sulfuric acid, if desired in a reaction inert solvent.
  • compounds of formula (l-b-1) may be prepared by reacting an intermediate of formula (XIX) with a carboxylic acid of formula (XX) or a functional derivative thereof.
  • Said functional derivative of (XX) is meant to comprise the halide, anhydride, amide and ester form of (XX), including the ortho and imino ester form thereof.
  • the cyclization of (XIX) and (XX) is preferably carried out by mixing the reactants, optionally in a reaction inert solvent such as, for example, water; a C1-6alkanol, e.g. methanol, ethanol, 1-butanol; an ester, e.g.
  • ethyl acetate ethyl acetate
  • a halogenated hydrocarbon e.g. trichloromethane, dichloromethane
  • a mixture of such solvents preferably in the presence of a mineral acid such as, for example, hydrochloric acid, sulfuric acid, or a carboxylic acid such as, for example, formic acid, acetic acid, or a sulfonic acid such as, for example, methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid or in the presence of an appropriate dehydrating agent such as for example, polyphosphoric acid, phosphorous pentoxide.
  • a mineral acid such as, for example, hydrochloric acid, sulfuric acid, or a carboxylic acid such as, for example, formic acid, acetic acid, or a sulfonic acid such as, for example, methanesulfonic, benzenesulfonic, 4-methylbenzenes
  • the cyclization reaction of (XIX) and (XX) may be conducted in the presence of a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide, polyphosphate ester.
  • a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide, polyphosphate ester.
  • the imino ester form of (XX) in an acidic medium such as, for example, acetic acid, or a C1-6alkanol, whereto an appropriate acid, e.g. hydrochloric acid has been added in case the imino ester is not in the form of an acid addition salt.
  • the compounds of formula (l-b-1) may also be obtained by cyclizing an intermediate of formula (XXI).
  • Said cyclization reaction may conveniently be conducted by heating intermediate (XXI) in an appropriate reaction-inert solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, a halogenated hydrocarbon, e.g., trichloromethane, tetrachloromethane, an alkanol, e.g., ethanol, propanol, butanol, a ketone, e.g., 2-propanone, 4-methyl-2-pentanone, a dipolar aprotic solvent, e.g., N,N-dimethylformamide N,N-dimethylacetamide, acetonitrile, pyridine, or a mixture of such solvents, and optionally removing the water which is liberated during the course of the cyclization reaction by azeo
  • an acid catalyst such as, for example, a mineral acid, e.g., hydrochloric, sulfuric acids, a carboxylic acid, e.g., acetic acid, trifluoroacetic acid, a sulfonic acid, e.g., methanesulfonic, benzenesulfonic or 4-methylbenzenesulfonic acid.
  • a mineral acid e.g., hydrochloric
  • sulfuric acids e.g., sulfuric acids
  • a carboxylic acid e.g., acetic acid, trifluoroacetic acid
  • a sulfonic acid e.g., methanesulfonic, benzenesulfonic or 4-methylbenzenesulfonic acid.
  • urea thiourea
  • 1,1'-sulfinylbis[1H-imidazole] 1,1'-carbonylbis[1_H-imidazole
  • alkylcarbonohalidates e.g., ethyl carbonochloridate, dialkylcarbonates
  • carbonoic dichloride carbonothioic dichloride
  • Said reaction may be carried out by stirring the reactants, optionally in a reaction-inert solvent such as, for example, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran; a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane; a hydrocarbon, e.g. benzene, methylbenzene; an alcohol, e.g. methanol, ethanol; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone; a polar aprotic solvent, e.g.
  • a reaction-inert solvent such as, for example, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran; a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane; a hydrocarbon, e.g. benzene, methylbenzene; an
  • a base such as, for example, an alkali or earth alkaline metal carbonate, hydrogen carbonate, hydroxide or oxide, for example, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, or an organic base, for example, N,N-diethylethanamine, N-(1-methylethyl)-2-pro- panamine.
  • a base such as, for example, an alkali or earth alkaline metal carbonate, hydrogen carbonate, hydroxide or oxide, for example, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, or an organic base, for example, N,N-diethylethanamine, N-(1-methylethyl)-2-pro- panamine.
  • the compounds of formula (I-b-2) can also be prepared by reducing and condensing an intermediate of formula (XXIII) in a reaction-inert solvent.
  • L 1 represents a reactive leaving group such as, for example, amino or alkyloxy, e.g., methoxy, ethoxy.
  • Reaction-inert solvents are, for example, alkanols, e.g., methanol, ethanol, butanol, aromatic hydrocarbons, e.g., benzene, methylbenzene, halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane.
  • Said reduction can conveniently be carried out by treating (XXIII) with a reducing agent such as, for example, an alkali metal borohydride, e.g. lithium, potassium or, preferably, sodium borohydride, sodium cyanoborohydride reducing agents.
  • the compounds of formula (I-b-3), may be prepared by reacting an intermediate of formula (XXIV) with ammonia. Said reaction may conveniently be conducted by stirring the reactants in an appropriate solvent such as, for example, and alkanol, e.g., methanol, ethanol, an ether, e.g., 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene, a halogenated hydrocarbon, e.g. trichloromethane, tetrachloromethane solvents.
  • an appropriate solvent such as, for example, and alkanol, e.g., methanol, ethanol, an ether, e.g., 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane, an aromatic hydrocarbon, e.g., benz
  • the compounds of formula (l-b-4), may be obtained from an intermediate of formula (XXV) wherein L represents a leaving group as defined hereinabove, by reaction with ammonia, following the procedures described hereinabove for the preparation of the compounds of formula (I-b-3) from the intermediates (XXIV).
  • Compounds of formula (Ilb-4) wherein R 19 is C 1-6 alkyl may be prepared by cyclizing an intermediate of formula (XXVI) in the presence of a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide.
  • a suitable dehydrating agent such as, for example, polyphosphoric acid, phosphorous pentoxide.
  • R 19-a represents C 1-6 alkyl.
  • the compounds of formula (I-b-6), may be prepared by reacting an intermediate (XXVIII) with a carboxylic acid of formula (XIX) or a functional derivative thereof.
  • Said functional derivative of (XXIX) is meant to include the halide, anhydride, amide and ester form of (XXIX), including the ortho and imino ester form thereof.
  • the cyclization is carried out according to similar procedures as described herein before for the preparation of (I-b-1) starting from (XIX) and (XX).
  • the quinoxaline compounds of formula (I-c) can alternatively be prepared under similar conditions as are described in the literature by condensing an appropriate ortho-disubstituted benzene with a two-carbon synthon.
  • the compounds of formula (I) wherein Z is a radical (c-1) and R 24 is hydrogen, C 1 - 6 alkyl or Ar 2 , said compound being represented by formula (I-c-1-a), may be obtained by condensing an appropriate ortho-benzenediamine of formula (XXX-a) with a 1,2-diketone of formula (XXXI).
  • R 24 -a represents hydrogen, C 1-6 alkyl or Ar 2 .
  • the condensation of the (1-H-azol-1-ylmethyl) substituted ortho-diamine of formula (XXX-a) and the 1,2-diketone of formula (XXXI) can be carried out by mixing the reactants in a suitable solvent such as, for example, an alkanol, e.g. methanol, ethanol, propanol; an ether, e.g. tetrahydrofuran, 1,4-dioxane, 1,1'- oxybisbutane; a halogenated hydrocarbon, e.g.
  • a suitable solvent such as, for example, an alkanol, e.g. methanol, ethanol, propanol; an ether, e.g. tetrahydrofuran, 1,4-dioxane, 1,1'- oxybisbutane; a halogenated hydrocarbon, e.g.
  • trichloromethane dichloromethane
  • a dipolar aprotic solvent e.g., N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide
  • an aromatic hydrocarbon e.g. benzene, methylbenzene, dimethylbenzene or mixtures of such solvents optionally in the presence of a carboxylic acid, e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • a carboxylic acid e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenes
  • 1,2-diketones of formula (XXXI) there may be named for example, ethanedial, diphenylethanedione, 2,3-butanedial two carbon synthons.
  • the compounds of formula (I) wherein Z is a radical of formula (c-2) and n is 0, said compounds being represented by (I-c-2-a), may be obtained by condensing an appropriate ortho-benzenediamine of formula (XXX-b) with an appropriate a-keto acid of formula (XXXII) or a functional derivative thereof such as, for example, an ester, a halide.
  • the condensation of the (1H-azol-1-ylmethyl) substituted ortho-diamine of formula (XXX-b) and the a-keto acid or ester of formula (XXXII) can be carried out by mixing the reactants in a suitable solvent such as, for example, water, an alkanol, e.g.
  • methanol, ethanol, propanol e.g. tetrahydrofuran, 1,4-dioxane, 1,1'-oxybisbutane; a halogenated hydrocarbon, e.g. trichloromethane, dichloromethane; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide; an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; and mixtures of such solvents optionally in the presence of a carboxylic acid, e.g.
  • acetic acid a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • a-keto esters there may be named for example, ethyl 2-oxopropanoate, ethyl 4-methyl-2-oxopentanoate, ethyl 3-methyl-2-oxobutanoate, methyl ⁇ -oxoben- zeneacetate, diethyl 2-methyl-3-oxo-1,4-butanedioate, diethyl-1,3-propanedioate esters.
  • suitable halides there may be named 2-oxopropanoyl chloride, dichloroacetyl chloride, diethoxyacethyl chloride.
  • reaction of (XXX-b) with (XXXII) first yields an intermediate of formula (XXXIII-a) which may in situ or, if desired, after isolating and purifying it, be cyclized by heating it in the presence of an acid such as, for example, a carboxylic acid, e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • an acid such as, for example, a carboxylic acid, e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • the reduction and cyclization of (XXXIII-b) can conveniently be conducted by stirring the starting compound in a reaction inert solvent such as, for example, an alkanol, e.g. methanol, ethanol, propanol, an ester, e.g. ethyl acetate, butylacetate, an aromatic hydrocarbon, e.g. benzene, methylbenzene; a halogenated hydrocarbon, e.g. chloromethane in the presence of hydrogen and an appropriate metal catalyst such as, for example, palladium-on-charcoal, Raney nickel, optionally at an elevated temperature and/or pressure.
  • a reaction inert solvent such as, for example, an alkanol, e.g. methanol, ethanol, propanol, an ester, e.g. ethyl acetate, butylacetate, an aromatic hydrocarbon, e.g. benzene, methylbenzene; a halogenated hydrocarbon
  • the compounds of formula (I) wherein Z is a radical of formula (c-2) wherein n is 1, said compounds being represented by formula (I-c-2-b) may be prepared by cyclizing an ortho-nitroanilide containing a suitable activated methylenegroup of formula (XXXIV-a).
  • the base promoted cyclization of (XXXIV-a) can be conducted according to art-known cyclizing procedures as described in, for example, J. Chem. Soc., 1963, 2429; J. Med. Soc., 1966, 2285 and J. Org. Chem., 1968, 30, 201 by stirring, and optionally heating the ortho-nitroanilide (XXXIV-a) in a suitable solvent such as, for example water, an alcohol, e.g.
  • Suitable bases are for example, an alkaline metal or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide or hydride, e.g.
  • the obtained 3-substituted quinoxaline-N-oxide of formula (I-c-2-b) may be decomposed to give the corresponding unsubstituted N-oxide wherein R 27 is hydrogen.
  • the compounds of formula (I-c-2-b) can also be prepared by cyclizing an ortho anilide of formula (XXXIV-b).
  • P represents a suitable activating group such as, for example, C1 -4alkylcarbonyl, arylcarbonyl.
  • the base promoted cyclization of (XXXIV-b) can be carried out according similar procedures as described hereinabove for the cyclization of (XXXIV-a). Similar cyclization procedures are also outlined in J. Chem. Soc. 1963, p. 2431 and J. Chem. Soc. 1964, p. 2666
  • the quinoxaline-2,3-diones of formula (I-c-3) can be prepared by condensing an intermediate of formula (XXX-c) with oxalic acid (XXXV) or a functional derivative thereof such as, for example an ester or halide.
  • the condensation of (XXX-c) and (XXXV) is conveniently carried out by mixing the reactants, optionally in a reaction inert solvent such as, for example, water; an alkanol, e.g. methanol, ethanol; a halogenated hydrocarbon, e.g. trichloromethane, dichloromethane; an ether, e.g.
  • a dipolar aprotic solvent e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene; an ester, e.g. ethyl acetate or a mixture of such solvents optionally in the presence of a carboxylic acid, e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid.
  • a carboxylic acid e.g. acetic acid, a mineral acid such as, for example hydrochloric acid, sulfuric acid, or a sulfonic acid such as, for example, methanesulfonic acid, benzenesulfonic acid, 4-methyl
  • reaction may even be carried out in an excess of carboxylic acid, e.g. acetic acid. Somewhat elevated temperatures may be appropriate to enhance the reaction and in some cases the reaction may even be carried out at the reflux temperature of the mixture.
  • carboxylic acid e.g. acetic acid.
  • Somewhat elevated temperatures may be appropriate to enhance the reaction and in some cases the reaction may even be carried out at the reflux temperature of the mixture.
  • the water or acid which is liberated during condensation may be removed by azeotropical distillation, distillation, complexation, salt formation methods.
  • the compounds of formula (I) wherein Z is a radical of formula (c-4) may be prepared by condensation of an ortho diamine of formula (XXX-d) with an a-halo acid of formula (XXXVI) or the ester form thereof
  • a suitable solvent such as, for example, water; an alkanol, e.g. methanol, ethanol, propanol; an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran; an ester, e.g. ethylacetate; a halogenated hydrocarbon, e.g.
  • an appropriate base such as, for example, an alkali metal carbonate, hydrogen carbonate or hydroxide, e.g. sodium carbonate, sodium hydrogen carbonate, ammonium hydroxide or an organic base such as, for example, N,N-diethylethanamine, may be utilized to pick up the acid which is liberated during the course of the reaction.
  • the a-ketotetrahydroquinoxalines of formula (I-c-4) wherein R 30 is hydrogen may be prepared by the reduction of an appropriately substituted ortho-nitrophenylglycine of formula (XXXVII).
  • the reduction of the ortho-nitrophenylglycine of formula (XXXVII) can conveniently be conducted by stirring the starting material in a reaction-inert solvent such as, for example, an alkanol, e.g. methanol, ethanol, propanol, an ester, e.g. ethyl acetate, butylacetate, an aromatic hydrocarbon, e.g.
  • benzene methylbenzene
  • a halogenated hydrocarbon e.g. chloromethane
  • an appropriate metal catalyst such as, for example, palladium-on-charcoal, Raney nickel, optionally at an elevated temperature and/or pressure.
  • the reduction may be carried out with sodium dithionite in the presence of acetic acid or in aqueous alkanol, e.g. an aqueous ethanol solution.
  • the compounds of formula (I-x) may also be prepared, for example, by cyclizing an intermediate of formula (XXXVIII) and desulfurating the thus obtained intermediate of formula (IXL).
  • R 35 represents hydrogen or C 1-6 alkyl and R 36 represents C 1-6 alkyl or both R 36 taken together form a C 2 - 3 alkanediyl radical.
  • Said cyclization reaction may conveniently be conducted by stirring and heating intermediate (XXXVIII) in an aqueous acidic solvent, e.g. in aqueous hydrochloric or sulfuric acid.
  • the intermediate (IXL) may be desulfurated following art-known procedures, e.g., by treatment with Raney nickel in the presence of an alkanol, e.g. methanol, ethanol, or by treatment with nitric acid, optionally in the presence of sodium nitrite.
  • the compounds of formula (I-y) may be prepared from a hydrazine derivative of formula (XL) by reaction with s-triazine following the procedures described in J. Org. Chem., 1956, 1037.
  • the compounds of formula (I) can also be converted into each other following art-known functional group transformation procedures.
  • the compounds of formula (1-a-1) wherein R 1 is hydrogen may be converted into compounds of formula (I-a-3) wherein R 7 is halo by treatment with a halogenating agent such as, for example, thionyl chloride, pentachlorophosphorane, phosphoryl chloride, sulfuryl chloride.
  • a halogenating agent such as, for example, thionyl chloride, pentachlorophosphorane, phosphoryl chloride, sulfuryl chloride.
  • the thus obtained compounds of formula (I-a-3) wherein R 7 is halo may further be converted into compounds of formula (I-a-3) wherein R 7 is C 1 - 6 alkyloxy by reacting the starting compound with an appropriate alcohol, preferably an alkali metal or earth alkaline metal salt of said alcohol.
  • the compounds of formula (I-a-1) may also be converted into compounds of formula (I-a-2), by a selective hydrogenation of the starting compound with an appropriate reducing agent such as, for example with a nobel catalyst, such as platinum-on-charcoal, palladium-on-charcoal. Dehydrogenation of the compounds of formula (I-a-2) may result in a compound of formula (I-a-1).
  • an appropriate reducing agent such as, for example with a nobel catalyst, such as platinum-on-charcoal, palladium-on-charcoal.
  • Dehydrogenation of the compounds of formula (I-a-2) may result in a compound of formula (I-a-1).
  • the dehydrogenation may be accomplished by stirring and optionally heating the starting compound with alkaline peroxide, ammoniacal silver nitrate, 2,3-dichloro-5,6-dicyano-p-benzoquinone manganese(IV)oxide, bromine in the presence of bromobenzen in suitable reaction-inert solvent.
  • suitable solvents for said dehydrogenation are, for example, water, alkanols, e.g. methanol, ethanol, ketones, e.g. 2-propanone, halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane, ethers, e.g.
  • 1,1-oxybisethane dipolar aprotic solvents, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, pyridine, or a mixture of such solvents.
  • dipolar aprotic solvents e.g. N,N-dimethylformamide, N,N-dimethylacetamide, pyridine, or a mixture of such solvents.
  • Some compounds of formula (I) may also be N-alkylated or N-aminated according to art known procedures.
  • the compounds of formula (I-b-4) wherein R 18 and R 19 are both hydrogen may be converted into compounds of formula (I-b-3) wherein R 17 is halo by treatment with a halogenating agent such as, for example, phosphoryl chloride, thionylchloride, pentachlorophosphorane, sulfurylchloride.
  • a halogenating agent such as, for example, phosphoryl chloride, thionylchloride, pentachlorophosphorane, sulfurylchloride.
  • R 17 is halo
  • R 17 is C 1-6 alkyloxy by reacting the starting compound with an appropriate alcohol, preferably an alkali metal or earth alkaline metal salt of said alcohol.
  • the compounds of formula (I-b-2) wherein R 15 is hydrogen may be converted into the corresponding compounds of formula (I-b-1).
  • the compounds of formula (I-b-3) can also be obtained by oxidizing a compound of formula (I-b-1) with an appropriate oxidizing reagent in a suitable reaction-inert solvent.
  • oxidizing reagents are, for example, permanganate or manganese(IV)oxide, silver oxide, silver nitrate, tert. butylhydroperoxide, hypochlorite, chromic acid, ferric chloride, ferric cyanide, lead tetra-acetate.
  • Suitable solvents for said oxidation reactions are, for example, water, alkanols, e.g. methanol, ethanol, ketones, e.g. 2-propanone, 4-methyl-2-pentanone, halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane, ethers, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane, dipolar aprotic solvents, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, pyridine, or a mixture of such solvents.
  • the compounds of formula (I-b-4) may be obtained from the compounds of formula (I-b-2).
  • the deoxygenation of the N-oxide of formula (I-c-2) can be carried out by stirring and, if desired, heating the starting compounds in a suitable solvent in the presence of hydrogen or hydrazine and an appropriate metal catalyst such as, for example, Raney nickel, Raney cobalt, platinum-on-charcoal, palladium-on-charcoal metal catalysts.
  • suitable solvents are water, an alkanol, e.g. methanol, ethanol, an ether, e.g. tetrahydrofuran, and mixtures of such solvents whereto an appropriate base has been added such as, for example, an alkali metal carbonate, hydrogen carbonate or hydroxide, e.g. sodium carbonate, sodium hydrogen carbonate, sodium hydroxide.
  • the deoxygenation of the N-oxide of formula (I-c-2-b) may be carried out with sodium dithionite in the presence of acetic acid or in an aqueous alkanol, e.g. an aqueous ethanol solution. It further proved possible to accomplish the deoxygenation by stirring the N-oxide in the presence of zinc and acetic acid.
  • a-ketotetrahydroquinoxalines of formula (I-c-4) may also be converted to a quinoxaline of formula (I-c-2) according to art-known dehydrogenation procedures as described for example J. Chem. Soc., 1953, 2816.
  • the dehydrogenation of the compounds of formula (I-c-4) can be carried out by heating the starting compound in an aqueous alkaline solution optionally in the presence of an appropriate oxidant such as, for example, peroxide, silver nitrate or manganese(IV) oxide.
  • Compounds of formula (I-c-5) can be obtained by reducing the corresponding compounds of formula (I-c-1) with an appropriate reducing agent such as, for example, an alkali metal borohydride, e.g. lithium, potassium or preferably, sodium borohydride, sodium cyanoborohydride reducing agents in a reaction inert solvent.
  • an appropriate reducing agent such as, for example, an alkali metal borohydride, e.g. lithium, potassium or preferably, sodium borohydride, sodium cyanoborohydride reducing agents in a reaction inert solvent.
  • Intermediates of formula (III), (V) and (VII-a) wherein Y is other than hydrogen may be prepared from an appropriately substituted quinoline or quinolinone, quinazoline or quinoxaline derivative of formula (XLII) according to the following reaction sequence.
  • the hydroxymethyl moiety in the starting intermediate of formula (XLII) is first converted into a formyl moiety with a suitable oxidant, e.g. manganese(IV) oxide or potassium permanganate, and subsequently reacted with a metal alkyl, e.g. methyllithium, butyllithium, metal aryl, e.g. phenyllithium, or with a complex metal alkyl or aryl in a suitable solvent, e.g.
  • the desired intermediates of formula (III) may then be obtained by converting the alcohol function of the intermediate of formula (V) into an appropriate leaving group W following standard procedures as known in the art.
  • halides are generally prepared by the reaction of (V) with an appropriate halogenating agent such as, for example, thionyl chloride, sulfuryl chloride, pentachlorophosphorane, pentabromophosphorane, phosphorylchloride, hydrochloric acid, hydrobromic acid halogenating agents.
  • the intermediates of formula (III) wherein Y is hydrogen can be obtained directly from the intermediates of formula (XLII) following the procedure described hereinabove for converting (V) into (III).
  • Some intermediates of formula (III) wherein Y is other than hydrogen may also be prepared by acylating a quinoline or quinolinone, quinazoline or quinoxaline of formula (XLIV) with an appropriate reagent of formula (XLIII) according to art-known Friedel-Crafts acylation reaction procedures, reducing the thus obtained ketone (VII-b) with an appropriate reductant, e.g. sodium borohydride in a suitable solvent such as water; an alcohol e.g. methanol, ethanol or mixtures thereof with tetrahydrofuran optionally in the presence of sodium hydroxide and subsequently converting the alcohol function into an appropriate leaving group as described hereinbefore.
  • an appropriate reductant e.g. sodium borohydride
  • an alcohol e.g. methanol, ethanol or mixtures thereof with tetrahydrofuran optionally in the presence of sodium hydroxide and subsequently converting the alcohol function into an appropriate leaving group as described hereinbefore.
  • Some intermediates of formula (III) may also be prepared by cyclizing an appropriate benzaldehyde or ketone derivative of the general formula (XLV) according to similar cyclization procedures as described hereinabove for the synthesis of the compounds of formula (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-b-1), (I-b-2), (I-b-3), (I-b-4), (I-b-5), (1-b-6), (I-c-1), (I-c-2), (I-c-3), (I-c-4) or (I-c-5) reducing the thus obtained quinoline, quinazoline, quinoxaline or quinolinone with an appropriate reductant, e.g.
  • Intermediates of formula (IX), (X)and (XI) can conveniently be prepared by reacting an aniline (VIII-a) with respectively a carboxylic acid of formula (XLVI-a), (XLVI-b) or (XLVI-c) or a functional derivative thereof.
  • Said functional derivatives of formula (XLVI-a), (XLVI-b) and (XLVI-c) are meant to comprise the halide, anhydride, amide and ester forms of (XLVI-a), (XLVI-b) and (XLVI-c).
  • (XLVI-a) may also be in the form of a reactive lactone such as, for example, 4-methylene-2-oxetanone.
  • Functional derivatives may be prepared following art-known procedures, for example, by reacting the carboxylic acid of formula (XLVI) with thionyl chloride, phosphorous trichloride, polyphosphoric acid, phosphoryl chloride, or by reacting the carboxylic acid of formula (XLVI) with an acyl halide, e.g. acetyl chloride, ethyl carbonochloridate.
  • the intermediates (VIII-a) and (XLVI) may be coupled in the presence of a suitable reagent capable of forming amides, e.g. 1,1'-carbonylbis[1_H-imidazole], dicyclohexylcarbodiimide, 2-chloro-1-methylpyridinium iodide.
  • Said amidation reactions may conveniently be carried out by stirring the reactants in a suitable reaction-inert solvent, such as, for example, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane, an aromatic hydrocarbon, e.g. methylenzene, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran or a dipolar aprotic solvent, e.g. N,N-dimethylformamide N,N-dimethylacetamide.
  • a suitable base may be appropriate, in particular a tertiary amine such as, N,N-diethylethanamine.
  • the water, the alcohol or the acid which is liberated during the course of the reaction may be removed from the reaction mixture according methodologies generally known in the art such as, for example, azeotropical distillation, complexation and salt formation.
  • reaction may be carried out according to similar procedures as outlined in Organic Synthesis, Willy New York, 1955, Collect. Vol. III page 10.
  • the intermediate of formula (XII) and/or (XIII) can be prepared by reducing the nitro derivative of formula (XLVII) in the presence of hydrogen and a suitable metal catalyst such as, for example, palladium-on-charcoal, platinum oxide catalysts.
  • the nitro derivative of formula (XLVII) in turn can be prepared from an aldehyde of formula (XLVIII) by reacting the latter with a phosphorous ylide of formula (IL) or with an ylide of formula (L) prepared from a phosphonate.
  • R 37 represents hydrogen or C,-4alkyl.
  • reaction of (XLVIII) with (IL) or (L) can conveniently he conducted by treating a phosphonium salt or a phosphonate with an appropriate base such as, for example, butyllithium, methyllithium, sodium amide, sodium hydride, a sodium or potassium alkoxide, sulfinylbis(methane) sodium salt bases, under an inert atmosphere and in a reaction-inert solvent such as for example, a hydrocarbon, e.g. hexane, heptane, cyclohexane; an ether, e.g.
  • an appropriate base such as, for example, butyllithium, methyllithium, sodium amide, sodium hydride, a sodium or potassium alkoxide, sulfinylbis(methane) sodium salt bases, under an inert atmosphere and in a reaction-inert solvent such as for example, a hydrocarbon, e.g. hexane, heptane, cycl
  • a dipolar aprotic solvent e.g. dimethylsulfoxide, hexamethylphosphor triamide, solvents.
  • W 1 represents a reactive leaving group such as, for example, halo, e.g. chloro or fluoro, nitro, 4-methylbenzenesulfonyloxy, phenyloxy, alkyloxy groups.
  • a sulfonic acid e.g. methanesulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid acids.
  • the starting compounds of formula (VIII) can easily be prepared according to procedures described in U.S. Patent No. 4,859,684 corresponding to EP-A-260,744 incorporated herein by reference for the process of preparing the intermediate of formula (VIII).
  • quinazoline compounds More particularly intermediates to prepare quinazoline compounds may be prepared as follows.
  • the intermediates of formula (XIX) can generally be prepared from amides, ureas or carbamates of formula (XXI-a) following art-known hydrolysis procedures, for example, by treating said amides, ureas or carbamates (XXI-a) with an acidic or basic aqueous solution, optionally at an enhanced temperature.
  • R 38 represents either C i - 6 alkyl, trifluoromethyl, Ar 2 or Ar 2- C l - 6 alkyl; or C 1-6 alkyloxy, amino or mono- or di(C 1-6 alkyl)amino.
  • the intermediates of formula (XXI-a) can be prepared by reducing an imine of formula (XXIII-a) following art-known reduction procedures such as, for example, reduction with an alkali metal borohydride, e.g. lithium, potassium, or preferably, sodium borohydride, sodium cyanoborohydride reagents, in a reaction-inert solvent such as, for example, an alkanol, e.g. methanol, ethanol.
  • an alkali metal borohydride e.g. lithium, potassium, or preferably, sodium borohydride, sodium cyanoborohydride reagents
  • a reaction-inert solvent such as, for example, an alkanol, e.g. methanol, ethanol.
  • the imines of formula (XXIII-a) in turn are prepared from an aldehyde of formula (XXIV-a) by reaction with an amine of formula R 14 -NH 2 in a reaction-inert solvent in the presence of an appropriate acid catalyst such as, for example, a sulfonic acid, e.g. methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid acid catalysts.
  • an appropriate acid catalyst such as, for example, a sulfonic acid, e.g. methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic acid acid catalysts.
  • the aldehydes of formula (XXIV-a) can prepared from a derivative of formula (LX) wherein P represents a protected carboxaldehyde group or a protected hydroxymethyl group, by hydrolysis of the protective group and in the case of the hydroxymethyl group, oxidation to the carboxaldehyde group.
  • suitable protective groups for hydroxymethyl are, for example, tetrahydropyranyl, 2-methoxyethoxymethyl, 2-methoxypropyl, 2-acetoxypropyl, 1-ethoxyethyl; a trialkylsilyl group, e.g. trimethylsilyl, tert. butyldimethylsilyl groups.
  • Suitable protective groups for carboxaldehyde are acyclic acetals formed with C i - 6 alkanols such as methanol, ethanol; or cyclic acetals formed with diols such as, 1,2-ethanediol, 1,3-propanediol. Said deprotection reactions can easily be conducted following art-known methods of hydrolyzing acetals and silyl ethers, e.g. by acid hydrolysis in aqueous media.
  • Said oxidation of a hydroxymethyl to a carboxaldehyde group can conveniently be conducted by oxidation with a suitable oxidizing agent such as, for example, manganese (IV) oxide; permanganate salts, e.g. potassium permanganate; dimethylsulfoxide with a dehydrating reagent, e.g. oxalylchloride, sulfur trioxide, dicyclohexylcarbodiimide.
  • Suitable solvents for said oxidation are, for example, water, halogenated hydrocarbons, e.g. dichloromethane, trichloromethane, tetrachloromethane.
  • the protected intermediates of formula (LX) are generally prepared from ketones of formula (LXI) following reaction sequences as described hereinabove for the conversion of ketones of formula (VII) into compounds of formula (I).
  • the intermediates of formula (LXI) are obtained from a suitably substituted nitrobenzene (LXII) by reduction following art-known nitro-to-amino reduction procedures, e.g. catalytic hydrogenation with Raney nickel, palladium-on-charcoal; and subsequently acylating the thus obtained aniline with a C 1 - 6 alkanoic halide or anhydride, a C i - 6 alkylcarbonohalidate, e.g. ethyl carbonochloridate, 1,1,-dimethylethyl carbonochloridate acylating reagents.
  • the intermediates of formula (XXVII) wherein R 20 and R 21 are hydrogen or those of formula (XXVIII) wherein R 23 is hydrogen, said intermediates being represented by formula (LXIV), may, for example, be prepared from an appropriately substituted nitrobenzenamine of formula (LXII) by converting the latter into the corresponding nitrobenzenenitrile by diazotation and subsequent reaction with a cyanide salt e.g. copper cyanide and/or sodium cyanide, and reducing the thus obtained nitrobenzenenitrile under a hydrogen atmosphere, in the presence of an appropriate catalyst such as, for example, Raney nickel.
  • the intermediates of formula (LXIV) can also be obtained from a ketone of formula (LXV) following the reaction sequences as described hereinabove for the conversion of ketones of formula (VII) into compounds of formula (I).
  • the intermediate ketones of formula (LXV) can be prepared from a suitably substituted 2-nitrobenzaldehyde of formula (LXVI) by reacting the aldehyde with hydroxylamine or an acid addition salt thereof and dehydrating the intermediate oxime to a benzenenitrile of formula (LXVII).
  • the thus obtained nitrile is further hydrolyzed to an amide group and the nitro group reduced to an amino group following art-known hydrolysis and reduction procedures.
  • the intermediates of formula (LXIX) inturn can be obtained from a 2-nitrobenzoic acid of formula (LXX) by N-acylation of an amine R 21- NH 2 following art-known amidation procedures and reduction of the nitro group to an amino group according to procedures described hereinabove, for example, in the conversion of (LXII) into (LXI). More particular intermediates to prepare quinoxaline compounds may be prepared according the following procedures.
  • the intermediates of formulae (XXXIII-b), (XXXIV-a) and (XXXIV-b) can conveniently be prepared by reacting an intermediate (LXXII) with a carboxylic acid of formula (LXXI-a), (LXXI-b) or (LXXI-c) or a functional derivative thereof.
  • Said functional derivative of (LXXI-a), (LXXI-b) or (LXXI-c) are meant to comprise the halide, a symmetrical or mixed anhydride, amide and ester forms of (LXXI-a), (LXXI-b) or (LXXI-c).
  • R 27 represents a C 1-4 alkylcarbonyl group in formula (LXXI-b) the hydroxyl group taken together with R 27 may also form a reactive lactone such as, for example, 4-methylene-2-oxetanone.
  • Functional derivatives may be prepared following art-known procedures, for example, by reacting the carboxylic acid of formula (LXXI) with thionyl chloride, phosphorous trichloride, polyphosphoric acid, phosphoryl chloride, or by reacting the carboxylic acid of formula (LXXI) with an acyl halide, e.g. acetyl chloride, ethyl carbonochloridate.
  • the intermediates (LXXI) and (LXXII) may be coupled in the presence of a suitable reagent capable of forming amides, e.g. dicyclohexylcarbodiimide, 1,1'-biscarbonyl[1_H-imidazole], 2-chloro-1-methylpyridinium iodide.
  • Said amidation reactions may conveniently be carried out by stirring the reactants in a suitable reaction-inert solvent, such as, for example, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane, an aromatic hydrocarbon, e.g. methylbenzene, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran or a dipolar aprotic solvent, e.g. N,N-dimethylformamide N,N-dimethylacetamide.
  • a suitable base may be appropriate, in particular a tertiary amine such as, N,N-diethylethanamine.
  • the water, the alcohol or the acid which is liberated during the course of the reaction may be removed from the reaction mixture according methodologies generally known in the art such as, for example, azeotropical distillation, complexation and salt formation.
  • the intermediate hydrazines (XL) and amines (XLI) may conveniently be prepared from a ketone of formula (VII) by reaction with either an acid addition salt thereof, or with hydroxylamine or hydrazine or an acid addition salt or a solvate thereof, and reducing the thus obtained oxime or hydrazone, for example, by catalytic hydrogenation in the presence of hydrogen and an appropriate hydrogenation catalyst, e.g. Raney nickel.
  • an appropriate hydrogenation catalyst e.g. Raney nickel.
  • the intermediates of formula (XXXVIII) can be prepared from an amine of formula (XLI) by reaction with a reagent of formula (LXXIII) and optionally S-alkylating the thus obtained thiourea with a C1-6alkylhalide.
  • the compounds of formula (I) and some of the intermediates in this invention have an asymmetric carbon atom in their structure.
  • This chiral center may be present in a R- and a S-configuration, this R- and S-notation being in correspondence with the rules described in Pure Appl. Chem., 1976, 45, 11-30.
  • Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids.
  • Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate staring materials, provided that the reaction occurs stereospecifically.
  • the compounds of the present invention have useful pharmacological properties. For example, they suppress the plasma elimination of retinoids, such as, all-trans-retinoic acid, 13-cis retinoic acid and their derivatives. The latter results in more sustained/higher tissue concentrations of retinoic acid and improved control of the differentiation and growth of various cell types.
  • some compounds inhibit the formation of androgens from progestines and/or inhibit the action of the enzyme complex aromatase which catalyses the formation of estrogens from androgenic steroids in mammals.
  • a number of compounds also show an inhibitory action on the biosynthesis of thromboxane A 2 .
  • retinoids such as, 13-cis-retinoic acid, all-trans-retinoic acid and their derivatives to modulate differentiation and proliferation in several cell types whether they are of epithelial or mesenchymal origin is extensively studied and reviewed in J. Clin. Chem. Clin, Biochem., 26, 479-488 (1983); Pharmacological Reviews 36, 935-1005, (1984), Arch. Dermatol. 117, 160-180; (1981) and Journal of Medicinal Chemistry 25, 1269-1277, (1982).
  • the compounds can thus be used in the treatment of disorders which are characterized by an increased proliferation and/or abnormal differentiation of epithelial cells.
  • the compounds of the invention can be used for treatment of carcinoma which is essentially a derailment of cellular differentiation, occurring in epithelial tissues.
  • Other uses include, in addition to cancer treatment, the treatment of a variety of disorders of keratinization such as, for example, acne, psoriasis, lamellar ichthyosis, plantar warts, callosites, acanthosis nigricans, lechen planus, mol- luscum, melasma, corneal epithelial abrasion, geograpic tongue, Fox-Fordyce disease, cuteneous mestatic melanoma and heloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, and similar diseases.
  • disorders of keratinization such as, for example, acne, psoriasis, lamellar ichthyosis, plantar warts, callosites, a
  • the anti-tumor activity may be demonstrated in several retinoic acid-sensitive and insensitive cell lines and solid tumors such as, for example, in Ta3-Ha induced mamma tumors in female mice.
  • the inhibition of androgen and/or estrogen formation can be demonstrated by analyzing the effects of the compounds of the invention on the conversion of progestins into androgens in the presence of testicular microsomes or on the conversion of androstenedione into estrone and estradiol in the presence of human placental microsomes.
  • the in vivo-inhibition of androgen or estrogen formation can, for example, be demonstrated by measuring the suppression of the plasma testosterone or estrogen concentration in dogs, rats or mice. A number of relevant tests have been described in EP-A-260,744 and EP-A-293,978, both incorporated herein by reference.
  • the compounds can be used in the treatment of estrogen or androgen dependent disorders such as, for example, breast cancer, endometriosis, endometrial cancer, polycystic ovarian disease, benign breast disease, prostatic cancer and hirsutism.
  • the present invention provides a method for treating mammals suffering from disorders which are characterized by an increased proliferation and/or abnormal differentiation of normal, preneoplastic or neoplastic cells, whether they are epithelial or mesenchymal; whether they are of ectodermal, endodermal or mesodermal origin; or whether they are estrogen dependent, androgen dependent or nonestrogen and nonandrogen dependent.
  • Said method comprises the systemic or topical administration to the latter of an amount, effective to treat said disorders, of a compound of formula (I), a pharmaceutically acceptable acid-addition salt, or a possible stereochemically isomeric form thereof.
  • the present invention provides a method in which the growth and differentiation in said normal, preneoplastic and neoplastic cells is sensitive to the actions of retinoids.
  • an effective amount would be from 0.001 mg/kg to 50 mg/kg body weight and more preferably from 0.01 mg/kg to 10 mg/kg body weight.
  • compositions for administration purposes.
  • compositions there may be cited all compositions usually employed for system- ically or topically administering drugs.
  • an effective amount of the particular compound, optionally in acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents in the case of powders, pills, capsules, and tablets.
  • solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents may be employed.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • compositions usually employed for topically administering drugs e.g., creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders.
  • Application of said compositions may be by aerosol e.g. with a propellent such as nitrogen carbon dioxide, a freon, or without a propellent such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab.
  • a propellent such as nitrogen carbon dioxide, a freon
  • a propellent such as a pump spray
  • drops lotions
  • a semisolid such as a thickened composition which can be applied by a swab.
  • semisold compositions such as salves, creams, gellies, ointments will conveniently be used.
  • Dosage unit form as used in the specification and claims herein refers to physically discreate units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powders packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls, and segregated multiples thereof.
  • compositions are preparations of the cosmetic type, such as toilet waters, packs, lotions, skin milks or milky lotions.
  • Said preparations contain, besides the active ingredient, components usually employed in such preparations.
  • components usually employed in such preparations.
  • examples of such components are oils, fats, waxes, surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols.
  • further ingredients may be incorporated in the compositions, e.g. antiinflammatory agents, antibacterials, antifungals, disinfectants, vitamins, sunscreens, antibiotics, or other anti-acne agents.
  • oils comprise fats and oils such as olive oil and hydrogenated oils; waxes such as beeswax and lanolin; hydrocarbons such as liquid paraffin, ceresin, and squalane; fatty acids such as stearic acid and oleic acid; alcohols such as cetyl alcohol, stearyl alcohol, lanolin alcohol, and hexadecanol; and esters such as isopropyl myristate, isopropyl palmitate and butyl stearate.
  • oils comprise fats and oils such as olive oil and hydrogenated oils; waxes such as beeswax and lanolin; hydrocarbons such as liquid paraffin, ceresin, and squalane; fatty acids such as stearic acid and oleic acid; alcohols such as cetyl alcohol, stearyl alcohol, lanolin alcohol, and hexadecanol; and esters such as isopropyl myristate, isopropyl palmitate and butyl
  • anionic surfactants such as sodium stearate, sodium cetylsulfate, polyoxyethylene lauryl-ether phosphate, sodium N-acyl glutamate; cationic surfactants such as stearyldimethyl-benzylammonium chloride and stearyltrimethylammonium chloride; ampholytic surfac-tants such as alkylaminoethylglycine hydrochloride solutions and lecithin; and nonionic surfactants such as glycerin monostearate, sorbitan monostearate, sucrose fatty acid esters, propylene glycol monostearate, polyoxyethylene oleylether, polyethylene glycol monostearate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene coconut fatty acid monoethanolamide, pelyoxyethylene polyoxypropylene glycol (e.g.
  • humectants include glycerin, 1,3-butylene glycol, and propylene glycol
  • examples of lower alcohols include ethanol and isopropanol
  • examples of thickening agents include xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene glycol and sodium carboxymethyl cellulose
  • examples of antioxidants comprise butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, citric acid and ethoxyquin
  • examples of chelating agents include disodium edetate and ethanehydroxy diphosphate
  • examples of buffers comprise citric acid, sodium citrate, boric acid, borax, and disodium hydrogen phosphate
  • examples of preservatives are methyl parahydroxybenzoate, ethyl parahydroxybenzoate, dehydroacetic acid, salicylic acid and benzo
  • the carrier for example consists of 1 to 20%, in particular 5 to 15% of a humectant, 0.1 to 10% in particular from 0.5 to 5% of a thickener and water; or said carrier may consist of 70 to 99%, in particular 20 to 95% of a surfactant, and 0 to 20%, in particular 2.5 to 15% of a fat; or 80 to 99.9% in particular 90 to 99% of a thickener; or 5 to 15% of a surfactant, 2-15% of a humectant, 0 to 80% of an oil, very small ( ⁇ 2%) amounts of preservative, colouring agent and/or perfume, and water.
  • the carrier for example consists of 2 to 10% of a lower alcohol, 0.1 to 10% or in particular 0.5 to 1% of a surfactant, 1 to 20%, in particular 3 to 7% of a humectant, 0 to 5% of a buffer, water and small amounts ( ⁇ 2%) of preservative, dyestuff and/or perfume.
  • the carrier typically consists of 10-50% of oil, 1 to 10% of surfactant, 50-80% of water and 0 to 3% of preservative and/or perfume.
  • all % symbols refer to weight by weight percentage.
  • the humectant, surfactant, oil, etc... referred to in said preparations may be any such component used in the cosmetic arts but preferably will be one or more of the components mentioned hereinabove.
  • compositions for use in the method of the present invention are those wherein the active ingredient is formulated in liposome-containing compositions.
  • Liposomes are artificial vesicles formed by amphiphatic molecules such as polar lipids, for example, phosphatidyl cholines, ethanolamines and serines, sphingomyelins, cardiolipins, plasmalogens, phosphatidic acids and cerebiosides. Liposomes are formed when suitable amphiphathic molecules are allowed to swell in water or aqueous solutions to form liquid crystals usually of multilayer structure comprised of many bilayers separated from each other by aqueous material (also referred to as coarse liposomes).
  • Another type of liposome known to be consisting of a single bilayer encapsulating aqueous material is referred to as a unilamellar vesicle. If water-soluble materials are included in the aqueous phase during the swelling of the lipids they become entrapped in the aqueous layer between the lipid bilayers.
  • compositions which comprise an inert carrier, an effective amount of a compound of formula (I) an acid addition salt or a stereochemically isomeric form thereof and an effective amount of a retinoic acid, a derivative thereof or a stereochemically isomeric form thereof.
  • Said retinoic acid containing compositions are particularly useful for treating acne or for retarding the effects of aging of the skin and generally improve the quality of the skin, particularly human facial skin.
  • a pharmaceutical or cosmetical composition containing retinoic acid or a derivative thereof as the active ingredient in intimate admixture with a dermatologically acceptable carrier can be prepared according to conventional compounding techniques, such as those known for topical application of retinoic acid and its derivatives.
  • composition for topical application are in form of a cream, ointment or lotion comprising from 0.005 to 0.5% (particularly from 0.01 to 0.1 %) all-trans-retinoic acid, 13-cis-retinoic acid or a derivative thereof and from 0.1 to 5% of a compound of formula (I) and, a dermatologically acceptable acid addition salt thereof or a stereochemically isomeric form thereof, in a semi-solid or liquid diluent or carrier.
  • compositions should preferably be non-irritating and as far as possible they should be odorless and non-toxic.
  • the composition usually contain, besides water or an organic solvent, several of certain organic emollients, emulsifiers for the aqueous and/or non aqueous phases of the compositions, wetting agents preservatives and agents that facilitate the penetration and remainence of the active agents in the skin.
  • a mixture of 15 parts of a-phenyl-6-quinolinemethanol, 21 parts of 1,1'-carbonylbis[1_H-imidazole] and 135 parts of N,N-dimethylformamide was stirred for 12 hours at room temperature. After evaporation to dry, the residue was stirred for 20 minutes at room temperature in a mixture of 140 parts of 1,1'-oxybisethane and 200 parts of water. The mixture was filtered and the filtrate was extracted with trichloromethane and water. The separated organic phase was dried, filtered and evaporated.
  • the residue was purified by column over silica gel, first using a mixture of dichloromethane and methanol (98:2 by volume) and then a mixture of ethyl acetate and cyclohexane (70:30 by volume) as eluents. The pure fractions were collected and the eluent was evaporated. The residue was converted into the sulfate salt in 8 parts of 2-propanone and ethanol at 0°C. The salt was filtered off and crystallized from a mixture of 2-propanol and methanol.
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-a). One hour later, the animals were anesthetized with ether and injected intrajugularly with 0.50 ml saline solution containing 20 ⁇ g of all-trans-retinoic acid. Two hours after this injection, rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization.
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-a).Two hours after drug administration, the rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization. Under the conditions used, plasma concentrations of the retinoic acid in vehicle-pretreated animals were not detectable ( ⁇ 0.5 ng/ml), whereas compound nos.
  • the product was crystallized successively from a mixture of ethyl acetate and 2,2'-oxybispropane and from ethyl acetate.
  • the product was filtered off, washed with a mixture of ethyl acetate and 2,2'-oxybispropane and dried in vacuo at 50 °C, yielding 5.30 parts (32.4%) of 5-benzoyl-2-nitrobenzonitrile; mp. 121.8°C (interm. 13-b).
  • a solution of 6.5 parts of the residue in 75 parts of a hydrochloric acid solution 3 N was stirred for 2 hours at reflux temperature.
  • the reaction mixture was evaporated to dry and the residue was dissolved in a potassium carbonate solution 40%.
  • the product was extracted with a mixture of dichloromethane and ethanol.
  • the extract was dried, filtered and evaported.
  • the residue was purified by column chromatography over silica gel using a mixture of dichloromethane, methanol and ammonium hydroxide (90:10:0.1 by volume) as eluent.
  • the pure fractions were collected and the eluent was evaporated.
  • the residue was converted into the hydrochloride salt in ethanol.
  • the salt was filtered off and crystallized from methanol.
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-b). One hour later, the animals were anesthetized with ether and injected intrajugularly with 0.50 ml saline solution containing 20 ⁇ g of all-trans-retinoic acid. Two hours after this injection, rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization.
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-b). Two hours after drug administration, the rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization. Under the conditions used, plasma concentrations of the retinoic acid in vehicle-pretreated animals were not detectable ( ⁇ 0.5 ng/ml), whereas compound nos. 18-b, 19-b, 20-b, 24-b, 38-b, 42-b, 43-b and 46-b enhanced the recovery of all-trans-retinoic acid from the plasma to a least 1 ng/ml.
  • the first product was filtered off and dried, yielding 1.25 parts (12.3%) of 7-[1-(1H-imidazol-1-yl)-2-methylpropyl]-2(1H)-quinoxalinone; mp. 246.3 ° C (comp. 90-c).
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-c). One hour later, the animals were anesthetized with ether and injected intrajugularly with 0.50 ml saline solution containing 20 I.Lg of all-trans-retinoic acid. Two hours after this injection, rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization.
  • mice Male Wistar rats weighing 200-210 g were orally treated with vehicle (PEG 200) or with 40 mg/kg of a compound of formula (I-c). Two hours after drug administration, the rats were killed by decapitation and blood was collected on heparin. Blood samples were centrifuged (1000 g, 15 min) and plasma was recovered to determine the quantity of plasmatic all-trans-retinoic acid. The samples were analyzed by means of HPLC with UV-detection at 350 nm. Quatification was achieved by peak area integration and external standardization. Under the conditions used, plasma concentrations of the retinoic acid in vehicle-pretreated animals were not detectable ( ⁇ 0.5 ng/ml), whereas compound nos.
  • vehicle PEG 200
  • I-c a compound of formula
  • Active ingredient as used throughout these examples relates to a compound of formula (I), a N-oxide form, a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.
  • the wet powder mixture was sieved, dried and sieved again.
  • the whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 0.01 g of the active ingredient.
  • Example 47 2% cream
  • Stearyl alcohol, 2 mg cetyl alcohol, 20 mg sorbitan monostearate and 10 mg isopropyl myristate are introduced into a doublewall jacketed vessel and heated until the mixture has completely molten.
  • This mixture is added to a separately prepared mixture of purified water, 200 mg propylene glycol and 15 mg polysorbate 60 having a temperature of 70 to 75 °C while using a homogenizer for liquids.
  • the resulting emulsion is allowed to cool to below 25°C while continuously mixing.
  • a solution of 20 mg A.I., 1 mg polysorbate 80 and purified water and a solution of 2 mg sodium sulfite anhydrous in purified water are next added to the emulsion while continuously mixing.
  • the cream, 1 g of the A.I. is homogenized and filled into suitable tubes.
  • Example 48 2% topical gel
  • Example 49 2% topical cream
  • Example 50 2% liposome formulation
  • a mixture of 2 g A.I. microfine, 20 g phosphatidyl choline, 5 g cholesterol and 10 g ethyl alcohol is stirred and heated at 55-60 °C until complete solution and is added to a solution of 0.2 g methyl paraben, 0.02 g propyl paraben, 0.15 g disodium edetate and 0.3 g sodium chloride in purified water while homogenizing. 0.15 g Hydroxypropylmethylcellulose in purified water ad 100 g is added and the mixing is continued until swelling is complete.
  • Example 51 2% liposome formulation
  • a mixture of 10 g phosphatidyl choline and 1 g cholesterol in 7.5 g ethyl alcohol is stirred and heated at 40°C until complete solution.
  • 2 g A.I. microfine is dissolved in purified water by mixing while heating at 40 °C.
  • the alcoholic solution is added slowly to the aqueous solution while homogenizing during 10 minutes.
  • 1.5 g Hydroxypropylmethylcellulose in purified water is added while mixing until swelling is complete.
  • the resulting solution is adjusted to pH 5.0 with sodium hydroxide 1 N and diluted with the rest of the purified water ad 100 g

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP89203014A 1988-11-29 1989-11-28 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives Expired - Lifetime EP0371564B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB888827821A GB8827821D0 (en) 1988-11-29 1988-11-29 (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827821 1988-11-29
GB8827820 1988-11-29
GB888827822A GB8827822D0 (en) 1988-11-29 1988-11-29 (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827822 1988-11-29
GB888827820A GB8827820D0 (en) 1988-11-29 1988-11-29 (1h-azol-1-ylmethyl)substituted quinoline derivatives

Publications (3)

Publication Number Publication Date
EP0371564A2 EP0371564A2 (en) 1990-06-06
EP0371564A3 EP0371564A3 (en) 1991-05-29
EP0371564B1 true EP0371564B1 (en) 1995-07-12

Family

ID=27264207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP89203014A Expired - Lifetime EP0371564B1 (en) 1988-11-29 1989-11-28 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives

Country Status (22)

Country Link
EP (1) EP0371564B1 (da)
JP (1) JP2916181B2 (da)
CN (3) CN1033752C (da)
AT (1) ATE124941T1 (da)
AU (1) AU620946B2 (da)
CA (1) CA2002864C (da)
CY (1) CY1920A (da)
DE (1) DE68923430T2 (da)
DK (1) DK172748B1 (da)
ES (1) ES2088889T3 (da)
FI (1) FI101964B1 (da)
GR (1) GR3017351T3 (da)
HK (1) HK118196A (da)
HU (2) HU205106B (da)
IE (1) IE67803B1 (da)
IL (1) IL92486A (da)
MY (1) MY105871A (da)
NO (1) NO174509B (da)
NZ (1) NZ231441A (da)
PT (1) PT92448B (da)
RU (1) RU1780536C (da)
ZW (1) ZW15889A1 (da)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7129356B2 (en) 2000-12-27 2006-10-31 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7179825B2 (en) 1997-12-11 2007-02-20 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7652014B2 (en) 2003-12-10 2010-01-26 Janssen Pharmaceutica Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
US7879857B2 (en) 2003-12-05 2011-02-01 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
CN1882547B (zh) * 2003-11-20 2011-04-13 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的6-烯基和6-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
US7928104B2 (en) 2003-11-20 2011-04-19 Dominique Jean-Pierre Mabire 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US8623884B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinedione derivatives as PARP inhibitors
US8623872B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinone derivatives as PARP inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
US8946221B2 (en) 2004-06-30 2015-02-03 Janssen Pharmaceutica, Nv Phthalazine derivatives as PARP inhibitors
WO2015057626A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132340T2 (de) * 1990-11-06 2001-02-08 Yamanouchi Pharmaceutical Co., Ltd. Kondensiertes pyrazinderivat
DE4107038A1 (de) * 1991-03-01 1992-09-03 Schering Ag Triheteroarylmethane, verfahren zu deren herstellung, pharmazeutische praeparate die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
ATE143013T1 (de) * 1992-10-27 1996-10-15 Janssen Pharmaceutica Nv 4-chinolinyl derivate mit anti-helicobacter wirkung
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
AU664337B2 (en) * 1993-06-17 1995-11-09 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
TW316902B (da) * 1994-12-28 1997-10-01 Janssen Pharmaceutica Nv
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) * 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
UA71592C2 (uk) 1998-12-23 2004-12-15 Янссен Фармацевтика Н.В. Похідні 1,2-анельованого хіноліну, спосіб їх одержання (варіанти), фармацевтична композиція, що їх містить, проміжна сполука та спосіб її одержання
AU2001267852B2 (en) * 2000-06-30 2006-01-19 Msd K.K. Novel pyrazinone derivatives
AU2002214056A1 (en) * 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
KR100417705B1 (ko) * 2001-07-24 2004-02-11 한국화학연구원 4-아졸일-2-퀴놀리논 유도체 및 이를 포함하는 살균제조성물
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
ES2670349T3 (es) * 2003-11-20 2018-05-30 Janssen Pharmaceutica Nv 2-Quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de poli(ADP-ribosa) polimerasa
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
JP4643948B2 (ja) * 2004-08-23 2011-03-02 大日本住友製薬株式会社 キナゾリノン化合物の安定化方法
WO2007092839A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
US7868022B2 (en) 2006-02-06 2011-01-11 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
KR101307497B1 (ko) * 2006-04-19 2013-09-11 주식회사 동진쎄미켐 디이미다졸계 화합물 및 이를 이용한 유기발광소자
US7429589B2 (en) * 2006-04-27 2008-09-30 Hoffmann-La Roche Inc. Mono-nitration of aromatic compounds via nitrate salts
US20080076800A1 (en) * 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
MX2010008202A (es) 2008-01-28 2010-12-06 Janssen Pharmaceutica Nv Derivados de tio-2-aminoquinolina 6-sustituida utiles como inhibidores de beta-secretasa (bace).
AU2009228945B2 (en) 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
CA2850508A1 (en) * 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Imidazole derivatives as cyp17 inhibitors for the treatment of cancer
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
KR20150070348A (ko) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
BR112015008308A2 (pt) 2012-10-16 2017-12-05 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por metileno do ror-gama-t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
FR2629456B1 (fr) * 1988-03-31 1991-07-05 Esteve Labor Dr Derives des acides 7-(1-imidazolyl),1,4-dihydro-4-oxo-6,8-difluoro-1-cyclopropyl-3-quinoleincarboxylique, leur preparation et leur application en tant que medicaments

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579352B2 (en) 1997-12-11 2009-08-25 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US7179825B2 (en) 1997-12-11 2007-02-20 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
US7173040B2 (en) 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7053105B2 (en) 2000-09-25 2006-05-30 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
US7129356B2 (en) 2000-12-27 2006-10-31 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US7511138B2 (en) 2002-04-15 2009-03-31 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US7655654B2 (en) 2002-04-15 2010-02-02 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US8524714B2 (en) 2003-11-20 2013-09-03 Janssen Pharmaceutica, Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
US8450486B2 (en) 2003-11-20 2013-05-28 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
CN1882547B (zh) * 2003-11-20 2011-04-13 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的6-烯基和6-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
US7928104B2 (en) 2003-11-20 2011-04-19 Dominique Jean-Pierre Mabire 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US8071612B2 (en) 2003-12-05 2011-12-06 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US7879857B2 (en) 2003-12-05 2011-02-01 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
US7652014B2 (en) 2003-12-10 2010-01-26 Janssen Pharmaceutica Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
US9522905B2 (en) 2004-06-30 2016-12-20 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
US8623884B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinedione derivatives as PARP inhibitors
US8623872B2 (en) 2004-06-30 2014-01-07 Janssen Pharmaceutica, Nv Quinazolinone derivatives as PARP inhibitors
US8946221B2 (en) 2004-06-30 2015-02-03 Janssen Pharmaceutica, Nv Phthalazine derivatives as PARP inhibitors
US10150757B2 (en) 2004-06-30 2018-12-11 Janssen Pharmaceutica Nv Quinazolinone derivatives as PARP inhibitors
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
US9150540B2 (en) 2008-03-27 2015-10-06 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
US9598396B2 (en) 2008-03-27 2017-03-21 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
WO2015057626A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT

Also Published As

Publication number Publication date
HK118196A (en) 1996-07-12
NZ231441A (en) 1991-05-28
CN1036002C (zh) 1997-10-01
NO174509C (da) 1994-05-18
RU1780536C (ru) 1992-12-07
GR3017351T3 (en) 1995-12-31
IL92486A0 (en) 1990-08-31
MY105871A (en) 1995-02-28
CA2002864A1 (en) 1990-05-29
CN1033752C (zh) 1997-01-08
CN1106004A (zh) 1995-08-02
HU211686A9 (en) 1995-12-28
CN1042912A (zh) 1990-06-13
NO894734D0 (no) 1989-11-28
DE68923430T2 (de) 1996-02-15
ATE124941T1 (de) 1995-07-15
ES2088889T3 (es) 1996-10-01
HU896220D0 (en) 1990-02-28
FI101964B (fi) 1998-09-30
JPH02223579A (ja) 1990-09-05
AU620946B2 (en) 1992-02-27
DE68923430D1 (de) 1995-08-17
CY1920A (en) 1997-03-07
HUT52498A (en) 1990-07-28
IL92486A (en) 1993-07-08
IE893782L (en) 1990-05-29
CN1106005A (zh) 1995-08-02
AU4564689A (en) 1990-06-07
PT92448A (pt) 1990-05-31
ZW15889A1 (en) 1991-07-17
FI101964B1 (fi) 1998-09-30
EP0371564A3 (en) 1991-05-29
DK599489D0 (da) 1989-11-28
HU205106B (en) 1992-03-30
PT92448B (pt) 1995-07-18
EP0371564A2 (en) 1990-06-06
NO894734L (no) 1990-05-30
NO174509B (no) 1994-02-07
FI895687A0 (fi) 1989-11-28
IE67803B1 (en) 1996-05-01
DK172748B1 (da) 1999-06-28
DK599489A (da) 1990-05-30
CA2002864C (en) 1999-11-16
JP2916181B2 (ja) 1999-07-05
CN1036003C (zh) 1997-10-01

Similar Documents

Publication Publication Date Title
EP0371564B1 (en) (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives
US5151421A (en) (1h-azol-1-ylmethyl) substituted quinoxaline derivatives
US5037829A (en) (1H-azol-1-ylmethyl) substituted quinazoline derivatives
US7378433B2 (en) N-[4-(heteroarylmethyl)phenyl]-heteroarylamines
EP0293978B1 (en) (1h-azol-1-ylmethyl)substituted benzotriazole derivatives
US4943574A (en) (1H-azol-1-ylmethyl) substituted benzotriazole derivatives and pharmaceutical compositions containing them
KR0149162B1 (ko) (1h-아졸-1-일메틸) 치환된 퀴놀린, 퀴나졸린 또는 퀴녹살린 유도체
AU698199B2 (en) 6-{triazolyl{3-(trifluoromethyl)phenyl}methyl}-2- quinolinones and -quinolinethiones
EP0142190B1 (en) 1-(2-aryl-2-halo-1-ethenyl)-1h-azoles
US5268380A (en) (1H-azol-1-ylmethyl) substituted quinoline derivatives
US5185346A (en) (1H-azol-1-ylmethyl)substituted quinoline derivatives
AU652069B2 (en) 4-(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-5-methyl-3H- 1,2,4-triazol-3-one derivatives
US5039677A (en) 6-(1H-azol-1-ylmethyl)-1-(pyrimidinyloxy)-1H benzotriazoles
PH26050A (en) (1H-azol-1=ylmethyl)substituted benzotriazole derivatives
IE48762B1 (en) Heterocyclic derivatives of(4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1h-imidazoles and 1h-1,2,4-triazoles,processes for preparing them and compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19911122

17Q First examination report despatched

Effective date: 19930923

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE

REF Corresponds to:

Ref document number: 124941

Country of ref document: AT

Date of ref document: 19950715

Kind code of ref document: T

REF Corresponds to:

Ref document number: 68923430

Country of ref document: DE

Date of ref document: 19950817

ITF It: translation for a ep patent filed
ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: BA2A

Ref document number: 2088889

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3017351

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2088889

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2088889

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20050816

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20051012

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20051106

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20051107

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20051108

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20051111

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20051123

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20051124

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20051129

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20051213

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20051219

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061130

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070601

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070601

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20061128

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070601

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061128

BERE Be: lapsed

Owner name: *JANSSEN PHARMACEUTICA N.V.

Effective date: 20061130

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20061129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061130

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071128